Lancet - ENGAGE AF-TIMI 48 - Warfarin and Edoxaban

"Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial"

"Interpretation

CYP2C9 and VKORC1 genotypes identify patients who are more likely to experience early bleeding with warfarin and who derive a greater early safety benefit from edoxaban compared with warfarin.   

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61994-2/abstract